CureVac N.V. (ETR:5CV)
Germany · Delayed Price · Currency is EUR | Market Cap | 896.25M +42.2% |
| Revenue (ttm) | 70.74M -87.0% |
| Net Income | 128.82M +19.0% |
| EPS | 0.80 +94.0% |
| Shares Out | n/a |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 125,072 |
| Average Volume | 427,092 |
| Open | 3.896 |
| Previous Close | 3.878 |
| Day's Range | 3.862 - 3.960 |
| 52-Week Range | 2.000 - 4.900 |
| Beta | 1.87 |
| RSI | 43.60 |
| Earnings Date | Apr 24, 2026 |
About CureVac
As of December 18, 2025, CureVac N.V. was acquired by BioNTech SE. CureVac N.V., a biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid (mRNA). The company’s portfolio includes clinical and preclinical candidates for various disease indications in prophylactic vaccines, oncology, and molecular therapy. It also delivers optimized mRNAs to stimulate the production of therapeutic proteins utilizing its technology and instructs human cells to produce or secrete specific proteins in th... [Read more]
Financial Performance
Financial StatementsNews
BioNTech SE: BioNTech Closes Acquisition of CureVac N.V. Including Subsequent Offering Period to Strengthen its Unique Position in the mRNA Field
BioNTech has completed its exchange offer to acquire CureVacAcquisition complements BioNTech's capabilities and proprietary technologies in mRNA design, delivery formulations, and mRNA manufacturi...
CureVac Enters Oversold Territory (CVAC)
Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a tec...
BioNTech Secures Majority Of CureVac Shares As Exchange Offer Advances
(RTTNews) - BioNTech SE (BNTX) on Wednesday announced that 184 million shares of CureVac, which is about 81.74 percent of the total shares, were successfully submitted by the December 3 deadline.
BioNTech SE: BioNTech Achieves Minimum Condition in CureVac Exchange Offer
The minimum condition for the offer has been satisfied, with 184,071,410 shares of CureVac, representing approximately 81.74% of CureVac's issued and outstanding shares, tendered prior to the expir...
BioNTech Achieves Minimum Condition in CureVac Exchange Offer
The minimum condition for the offer has been satisfied, with 184,071,410 shares of CureVac, representing approximately 81.74% of CureVac's issued and outstanding shares, tendered prior to the expirati...
CureVac N.V. (CVAC) Shareholder/Analyst Call Prepared Remarks Transcript
CureVac N.V. ( CVAC) Shareholder/Analyst Call November 25, 2025 8:00 AM EST Company Participants Mehdi Shahidi Marco Rau Thaminda Ramanayake - Chief Business Officer & Member of Executive Board Alexa...
BioNTech (BNTX) Moves Forward with CureVac Acquisition
BioNTech (BNTX) Moves Forward with CureVac Acquisition
BioNTech (BNTX) Advances with Exchange Offer for CureVac Shares
BioNTech (BNTX) Advances with Exchange Offer for CureVac Shares
BioNTech’s exchange offer for German mRNA vaccine peer CureVac set to expire Dec. 3
Understood! Please provide the article or its content so I can generate the SEO-friendly meta description.
BioNTech SE: BioNTech Shares Progress on Exchange Offer for CureVac Shares and Highlights December 3, 2025, at 9:00 a.m. Eastern Time Expiration
Offer set to expire at 9:00 am Eastern Time on December 3, 2025, with CureVac shareholders advised to tender their shares by 6:00 pm Eastern Time on December 2, 2025, due to operational deadlines.E...
CureVac Announces Voting Results of Extraordinary General Meeting
TÜBINGEN, DE AND BOSTON, MA / ACCESS Newswire / November 25, 2025 / CureVac N.V. (Nasdaq:CVAC)(CureVac or the Company), a pioneering multinational biotech company developing a new class of transformat...
CureVac Reveals Key Voting Outcomes from Extraordinary Shareholder Meeting
CureVac’s latest Extraordinary General Meeting delivered near-unanimous backing for BioNTech’s exchange offer and key merger decisions, reshaping the company’s future.
EQS-News: CureVac Announces Voting Results of Extraordinary General Meeting • news
Company News for Nov 25, 2025
Companies In The News Are: CVAC, CAAP, NVO, BABA.
Nasdaq Surges 350 Points; Enlivex Therapeutics Shares Spike Higher
U.S. stocks traded higher this morning, with the Nasdaq Composite gaining more than 350 points on Monday. Following the market opening Monday, the Dow traded up 0.16% to 46,318.84 while the NASDAQ ros...
CureVac BV (CVAC) Reports Q3 Earnings with Strong Cash Position
CureVac BV (CVAC) Reports Q3 Earnings with Strong Cash Position
CureVac (CVAC) Reports Strong Cash Position as Strategic Measures Pay Off
CureVac (CVAC) Reports Strong Cash Position as Strategic Measures Pay Off
CureVac (CVAC) Reports Decrease in Q3 EPS
CureVac (CVAC) Reports Decrease in Q3 EPS
CureVac (CVAC) Moves Closer to BioNTech Deal for mRNA Innovations
CureVac (CVAC) Moves Closer to BioNTech Deal for mRNA Innovations
CureVac GAAP EPS of €1.21, revenue of €54.13M
CureVac Announces Financial Results for the Third Quarter and First Nine Months of 2025 and Provides Business Updates
German Federal Cartel Office clearance obtained for the planned BioNTech - CureVac transaction announced on June 12, 2025, marking an important step toward the expected closing later this year Offer p...
EQS-News: CureVac Announces Financial Results for the Third Quarter and First Nine Months of 2025 and Provides Business Updates
Issuer: CureVac / Key word(s): Quarterly / Interim Statement CureVac Announces Financial Results for the Third Quarter and First Nine Months of 2025 and Provides Business Updates 24.11.2025 / 13:10 CE...
CureVac is Now Oversold (CVAC)
Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a tec...
BioNTech (BNTX) Launches Exchange Offer for CureVac Shares
BioNTech (BNTX) Launches Exchange Offer for CureVac Shares
CureVac: The Hidden Value Of The mRNA Wallet
CureVac is a pioneering biotech company focused on mRNA drugs for oncology and vaccines. In biotech, value derives from research quality, patent strength, and clinical success probability, not current...